Drug Profile
NPT 088
Alternative Names: NPT-088Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator NeuroPhage Pharmaceuticals Inc
- Developer Proclara Biosciences
- Class Antidementias; Antiparkinsonians; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Nootropics; Recombinant fusion proteins
- Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Dec 2023 Discontinued - Phase-I for Alzheimer's disease in USA (IV) before December 2023
- 28 Dec 2023 Discontinued - Phase-I for Parkinson's disease in USA (IV) before December 2023
- 28 Sep 2021 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (IV)